Concepedia

Ray Pillai

RP

Statistics

Publications

6

Citations

406

H-Index

6

Active since

2009

Affiliations

New York University(Current)

NYU Langone Health

VA NY Harbor Healthcare System

Memorial Sloan Kettering Cancer Center

Princeton University

Ray Pillai is an author at New York University specializing in medicine, pharmacology, and nrf2 signaling pathway.

ORCID

Publications per year

2009–2025

6

Publications

6

KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance

Anastasia‐Maria Zavitsanou, Ray Pillai, Hao Yuan et al. · Cell Reports · 2023 · 131 citations · Full text

, , +17

Activation of the NRF2 antioxidant program sensitizes tumors to G6PD inhibition

Hongyu Ding, Zihong Chen, Katherine Wu et al. · Science Advances · 2021 · 91 citations · Full text

, , +17

Glutamine antagonist DRP-104 suppresses tumor growth and enhances response to checkpoint blockade in <i>KEAP1</i> mutant lung cancer

Ray Pillai, Sarah E. LeBoeuf, Yuan Hao et al. · Science Advances · 2024 · 59 citations · Full text

, , +3

QX-314 Produces Long-lasting Local Anesthesia Modulated by Transient Receptor Potential Vanilloid Receptors in Mice

Craig R. Ries, Ray Pillai, Cheryl C. W. Chung et al. · Anesthesiology · 2009 · 51 citations · Full text

, , +15

Targeting FSP1 triggers ferroptosis in lung cancer

Katherine Wu, Alec Vaughan, Jozef P. Bossowski et al. · Nature · 2025 · 49 citations · Full text

, , +14

1–5 of 6